DI-078 Economic impact evaluation of oseltamivir adjustment criteria in renal impairment
| Autor: | A Vila, A Lucas, M Calonge, A Parrilla, M Priegue |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Pediatrics
medicine.medical_specialty Oseltamivir education.field_of_study Cost effectiveness business.industry Population Renal function Retrospective cohort study Clinical trial chemistry.chemical_compound chemistry Pill medicine In patient General Pharmacology Toxicology and Pharmaceutics business education |
| Zdroj: | European Journal of Hospital Pharmacy. 23:A152.2-A153 |
| ISSN: | 2047-9964 2047-9956 |
| Popis: | Background The adjustment criteria for oseltamivir in patients with renal impairment are different depending on the source consulted. The different criteria lead to different dosage recommendations which are translated into different costs. Purpose To evaluate the economic impact of different adjustment criteria for oseltamivir in patients with renal impairment. Material and methods Observational retrospective study of patients treated with oseltamivir during the period 1 December 2014 to 31 March 2015. All patients hospitalised and treated with oseltamivir were included, except those in haemodialysis treatment. Data collected were: anthropometric data and glomerular filtrate (FG). Economic evaluation was carried out with the following official information: Tamiflu 75 mg/10 capsules, 31.57€ and Tamiflu 30 mg/10 capsules,17.39€. Renal impairment posology adjustment criteria were obtained from different databases: technical data of Tamiflu (TD), UptoDate, Micromedex, Sandford Guide to Antimicrobial Therapy 2013 (Sandford), Guia terapeutica antimicrobiana Mensa 2015 (Mensa) and Health Ministry Protocol (HMP). Pill consumption was estimated taking into account our population characteristics and the different adjustments for renal impairment criteria. Results 31 patients were treated, 100% adults, with a mean age of 66.23 years (64.74–67.71); 45.2% were women. Mean treatment duration was 5.45 (4.4–5.0) days. Stratificted by renal function: 21/31 patients had FG >60 mL/min, 8/31 had FG=60–30 mL/min and 2/31 had FG=30–10 mL/min. Two main adjustment criteria groups were found: criteria 1 (TD, Micromedex and UptoDate): FG >60 mL/min 75 mg/12 h; FG= 60–30 mL/min 30 mg/12 h; FG=30–10 mL/min 30 mg/24 h; and criteria 2 (HMP, Mensa, Sandford): FG >60 mL/min 75 mg/12 h, FG >30 mL/min 75 mg/12 h, FG=30–10 mL/min 75 mg/24 h. Both criteria were different from the FG Conclusion Posology adjustment following criteria 1 supposes a saving of 45%. This recommendation was offered by the hospital pharmacy department as it follows TD and is the most cost favourable. No clinical trials were found to justify adjustment criteria 2. It is necessary to know the influence of both criteria on treatment and stay duration to obtain a better cost effectiveness evaluation. Our sample did not have enough statistic power to establish differences in duration of stay for the different regimens. Further studies are needed to establish the most efficient adjustment criteria in terms of clinical results. References and/or Acknowledgements Micromedex. Intelligent information for clinicians (accessed July 2013). http://www.micromedex.com/ Mensa J, et al . Guia Terapeutica Antimicrobiana Antares, 2014 No conflict of interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|